ICMJE DISCLOSURE FORM

Date: March 10, 2024			
Your Name:	Matthew Dankner		
Manuscript Title	The evolving treatment landscape for BRAF-mutated non-small cell lung cancer		
Manuscript num	her (if known): TLCR-24-117		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	√ None		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events	,		
6	Payment for expert	_√_None		
	testimony			
_	C	,		
7	Support for attending meetings and/or travel	None		
	meetings and/or traver			
8	Patents planned, issued or	√ None		
	pending			
9	Participation on a Data	√ None		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	_√_None		
	in other board, society,			
	committee or advocacy			
11	group, paid or unpaid	/ **		
11	Stock or stock options	None		
12	Receipt of equipment,	/ None		
	materials, drugs, medical	None		
	writing, gifts or other			
	services			
13	Other financial or non- financial interests	_√_None		
Plea	Please summarize the above conflict of interest in the following box:			
N	None.			

Please place an "X" next to the following statement to indicate your agreement:

_x__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: March 7, 2024			
Your Name:	Jennifer Maxwell		
Manuscript Titl	e: The evolving treatment landscape for BRAF-mutated non-small cell lung cancer		
Manuscript nur	nber (if known): TLCR-24-117		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	✓_None	

5	Payment or honoraria for	_√ None		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
_	educational events	,		
6	Payment for expert testimony	_√_None		
	testimony			
7	Support for attending	/ N		
,	meetings and/or travel	None		
8	Patents planned, issued or	√ None		
	pending			
9	Participation on a Data	✓ None		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	_√_None		
	in other board, society,			
	committee or advocacy group, paid or unpaid			
11	Stock or stock options	√ None		
	Stock of Stock options	V_None		
12	Receipt of equipment,	√ None		
	materials, drugs, medical writing, gifts or other			
42	services	,		
13	Other financial or non- financial interests	None		
	illialiciai iliterests			
Ple	Please summarize the above conflict of interest in the following box:			
_				
	None.			

Please place an "X" next to the following statement to indicate your agreement:

_x__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: March 7	7, 2024		
Your Name:	April Rose		
Manuscript Ti	tle: The evolving trea	tment landscape for BRAF-mutated non-small cell lung cance	r
Manuscrint nu	ımber (if known):	TI CR-24-117	_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	
1	All support for the present	Canadian Cancer Society	Institution
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert	Advanced Accelerator Applications X None	myself
J	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	EMD Serono	myself
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	

Please summarize the above conflict of interest in the following box:

The author reports a Challenge grant from the Canadian Cancer Society (#707457), honoraria from Advanced Accelerator Applications for lectures, and honoraria from EMD Serono for participating in an advisory board, which is unrelated to the topics discussed in this manuscript.

Please place an "X" next to the following statement to indicate your agreement:

__x_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.